International Journal of Medical Sciences

Impact factor
2.399

19 October 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2014; 11(7):680-684. doi:10.7150/ijms.8916

Research Paper

New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation

Josep M. Alegret1✉, Xavier Viñolas2, Miguel A. Arias3, Antoni Martínez-Rubio4, Pablo Rebollo5, Carles Ràfols6, José L. Martínez-Sande7

1. Grup de Recerca Cardiovascular, Hospital Universitari de Sant Joan, IISPV, Universitat Rovira i Virgili, Reus, Spain.
2. Hospital de la Sta. Creu i St. Pau, Barcelona, Spain.
3. Hospital Virgen de la Salud, Toledo, Spain.
4. Hospital Universitari Parc Taulí, Sabadell, Spain.
5. LA-SER Outcomes, Oviedo, Spain.
6. Medical Department, Bayer HealthCare, Barcelona, Spain.
7. Hospital Clínico, Santiago de Compostela, Spain.

Abstract

New oral anticoagulants (NOAC) have demonstrated their efficacy as an alternative to vitamin K antagonists (VKA) in the prophylaxis of cardioembolic events in patients with atrial fibrillation (AF). However, evidence on the benefits of NOAC in health-related quality of life (HRQoL) is lacking.We evaluated changes in HRQoL related to oral anticoagulation therapy employing a specific questionnaire in a cohort of 416 patients with AF undergoing electrical cardioversion. In terms of HRQoL, we observed a progressive adaptation to treatment with VKA; satisfaction with NOAC remained constant. Older age, higher left ventricular ejection fraction and NOAC were associated with better HRQoL.

Keywords: vitamin K antagonists, dabigatran, health-related quality of life, new oral anticoagulants, ribaroxaban.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Alegret JM, Viñolas X, Arias MA, Martínez-Rubio A, Rebollo P, Ràfols C, Martínez-Sande JL. New Oral Anticoagulants vs Vitamin K Antagonists: Benefits for Health-Related Quality of Life in Patients with Atrial Fibrillation. Int J Med Sci 2014; 11(7):680-684. doi:10.7150/ijms.8916. Available from http://www.medsci.org/v11p0680.htm